<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180579</url>
  </required_header>
  <id_info>
    <org_study_id>19-277</org_study_id>
    <nct_id>NCT04180579</nct_id>
  </id_info>
  <brief_title>Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients</brief_title>
  <official_title>Safety and Tolerability of Lower Scalp Cooling Temperature to Prevent Doxorubicin Plus Cyclophosphamide and Paclitaxel-induced Alopecia in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if using the Paxman Scalp Cooling System at
      temperatures lower than the current standard is a safe and tolerable approach to prevent hair
      loss in breast cancer patients receiving chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by CTCAE</measure>
    <time_frame>Up to 44 weeks from the start of treatment</time_frame>
    <description>Safety will be determined by toxicity assessment according to CTCAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Cancer Stage I</condition>
  <condition>Breast Cancer Stage II</condition>
  <condition>Breast Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Participants with Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any adult woman with a new diagnosis of breast cancer, Stage I-III</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAXMAN Scalp Cooler</intervention_name>
    <description>Scalp cooling will occur with each dose of chemotherapy.</description>
    <arm_group_label>Participants with Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  New diagnosis of breast cancer stage I-III

          -  Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent

          -  Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline plus
             cyclophosphamide followed by taxane based chemotherapy regimen:

               -  Concurrent trastuzumab at standard doses is allowed

               -  Concurrent pertuzumab at standard doses is allowed

               -  Administration of chemotherapy on a dose dense schedule is allowed as clinically
                  indicated

          -  For women of childbearing potential, a negative pregnancy test is needed within 7 days
             prior to study intervention, or whenever collected as per standard of care

        Exclusion Criteria:

          -  Stage IV breast cancer or any other concurrent malignancy including hematological
             malignancies (i.e. leukemia or lymphoma)

          -  Baseline alopecia (defined CTCAE v5.0 grade &gt; 1)

          -  Subjects who are scheduled for bone marrow ablation chemotherapy

          -  Male gender

          -  Age &gt;/= 75 years

          -  Personal history of migraines, cluster or tension headaches as defined as actual
             medical diagnosis by a physician and/or prescribed medications. If personal history of
             migraines was related to a past medical problem that is now resolved, subject may go
             on study at the discretion of the Principal Investigator.

          -  Subjects who have had &gt;/=1 previous chemotherapy exposure resulting in alopecia

          -  An existing history of scalp metastases or suspected presence of scalp metastasis

          -  Subjects with cold sensitivity, cryoglobulinemia, cryofibrinogenemia, or cold migraine
             pot-traumatic cold dystrophy

          -  Previously received, or scheduled to undergo skull irradiation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shari Goldfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shari Goldfarb, MD</last_name>
    <phone>646-888-5080</phone>
    <email>goldfars@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Lacoutre, MD</last_name>
    <phone>646-888-6014</phone>
    <email>LacoutuM@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
    <contact_backup>
      <last_name>Mario Lacouture, MD</last_name>
      <phone>646-888-6014</phone>
    </contact_backup>
    <investigator>
      <last_name>Shari Goldfarb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alopecia</keyword>
  <keyword>breast cancer</keyword>
  <keyword>hair loss</keyword>
  <keyword>chemotherapy induced alopecia</keyword>
  <keyword>19-277</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

